Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Therapeutic antibodies against intracellular tumor antigens

Journal article

Trenevska I. et al, (2017), Frontiers in Immunology

The D0 Ig-like domain plays a central role in the stronger binding of KIR3DL2 to B27 free H chain dimers.

Journal article

Hatano H. et al, (2015), J Immunol, 194, 1591 - 1601

MicroRNAs and liver disease: viral hepatitis, liver fibrosis and hepatocellular carcinoma.

Journal article

Li G. et al, (2014), Postgrad Med J, 90, 106 - 112

The notch ligand JAGGED1 as a target for anti-tumor therapy.

Journal article

Li D. et al, (2014), Front Oncol, 4

A MOLECULAR BASIS FOR THE KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR KIR3DL2 BINDING TO HLA-B27 FREE HEAVY CHAIN DIMERS

Conference paper

Hatano H. et al, (2014), CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 32, 814 - 814

Molecular determinants for KIR3DL2 binding to HLA-B27 and other HLA-class I ligands

Conference paper

Hatano H. et al, (2013), IMMUNOLOGY, 140, 209 - 209

Molecular basis for Jagged-1/Serrate ligand recognition by the Notch receptor.

Journal article

Whiteman P. et al, (2013), J Biol Chem, 288, 7305 - 7312

HLA-B may be more protective against HIV-1 than HLA-A because it resists negative regulatory factor (Nef) mediated down-regulation.

Journal article

Rajapaksa US. et al, (2012), Proc Natl Acad Sci U S A, 109, 13353 - 13358

Identification of self-lipids presented by CD1c and CD1d proteins.

Journal article

Haig NA. et al, (2011), J Biol Chem, 286, 37692 - 37701

Load More